The group’s principle activities include detection, diagnosis, and treatment of breast cancer. The group’s products include Cancalert(TM) GP88 Biopsy Staining, Cancalert(TM) GP88 Serum Onitoring Kits, and Cancalert(TM)GP88 First Screen. The group operates from United States.